S*Bio (Cancer Drug Rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

S*Bio (Cancer Drug Rights) General Information

Description

Patent rights of Pracinostat, an oral histone deacetylase inhibitor. The drug portfolio consists of novel isoflavone-based drugs, ME-143 and ME-344.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 11455 El Camino Real
  • Suite 250
  • San Diego, CA 92130
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Corporate Office
  • 11455 El Camino Real
  • Suite 250
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

S*Bio (Cancer Drug Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore S*Bio (Cancer Drug Rights)‘s full profile, request access.

Request a free trial

S*Bio (Cancer Drug Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore S*Bio (Cancer Drug Rights)‘s full profile, request access.

Request a free trial

S*Bio (Cancer Drug Rights) FAQs

  • Where is S*Bio (Cancer Drug Rights) headquartered?

    S*Bio (Cancer Drug Rights) is headquartered in San Diego, CA.

  • What industry is S*Bio (Cancer Drug Rights) in?

    S*Bio (Cancer Drug Rights)’s primary industry is Buildings and Property.

  • Is S*Bio (Cancer Drug Rights) a private or public company?

    S*Bio (Cancer Drug Rights) is a Private company.

  • What is the current valuation of S*Bio (Cancer Drug Rights)?

    The current valuation of S*Bio (Cancer Drug Rights) is .

  • What is S*Bio (Cancer Drug Rights)’s current revenue?

    The current revenue for S*Bio (Cancer Drug Rights) is .

  • Who are S*Bio (Cancer Drug Rights)’s investors?

    S*BIO has invested in S*Bio (Cancer Drug Rights).

  • When was S*Bio (Cancer Drug Rights) acquired?

    S*Bio (Cancer Drug Rights) was acquired on 10-Aug-2012.

  • Who acquired S*Bio (Cancer Drug Rights)?

    S*Bio (Cancer Drug Rights) was acquired by Lite Strategy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process